Woman appears to be cured of HIV after using new treatment, NIH says
The woman appears to be HIV-free following a new transplant method using umbilical cord blood.
Source: fox10phoenix.com
Page 19 - Trial Network News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Trial Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Trial Network Today - Breaking & Trending Today
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial | Infectious Diseases | JAMA
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to sy
Source: jamanetwork.com
IDSA Reading Room | Florence Momplaisir, MD, MSPH, on HIV, Perinatal Depression, and ART Adherence
It is well known that women living with the human immunodeficiency virus (HIV) are at but the impact of depressive symptoms on antiretroviral therapy (ART) adherence and viral suppression (VS) during pregnancy, and the postpartum period, is less clear. A multi-center group of researchers analyzed longitudinal data from 1,869 women enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) P1025 Perinatal Core Protocol (2002-2013).
Source: medpagetoday.com
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18 - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com
INOVIO Highlights Key Updates - GuruFocus.com
GuruFocus Article or News written by PRNewswire and the topic is about:
Source: gurufocus.com